Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model
- Design
- Animal study · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Not human evidence[Auto] Non-human (animal or cellular) evidence; no direct inference to any human population.
- Could weight loss explain it?
- Unknown[Auto] Non-human study; weight-loss mediation not assessable.
- Study tier
- Study tier 4[Auto] Preclinical evidence; not clinical evidence for any human population.
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 20, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; last sentences of abstract] Co-therapy did not improve collagen deposition compared with monotherapy. These findings indicate that the combination of GLP-1 receptor agonism with cyclophilin inhibition does not confer additive antifibrotic benefits in this advanced MASLD model, underscoring stage-dependent constraints on therapeutic synergy.
01Findings
What the study reported
- Drugs
- Semaglutide
- Comparator
- monotherapy
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Baseline condition
- MASH / MASLD
Study quality details
- Study design
- Preclinical (animal)
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- intermediate
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- VERY_INDIRECT
- Statistical precision
- not extracted
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors have declared that no competing interests exist.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). Recently, approved drug treatments for MASLD, including thyroid hormone receptor beta (THR-β) and glucagon-like peptide-1 (GLP-1) receptor agonists, have been effective in treating the underlying metabolic causes of MASLD. However, more effective and acute treatments, particularly for already advanced or cirrhotic steatohepatitis, remain elusive. Other drug candidates, such as cyclophilin inhibitors, which have shown promise for treating advanced MASLD, are still under investigation. Because advanced MASLD reflects both upstream metabolic stress and downstream, self-sustaining injury responses promoting inflammation and fibrogenesis, we investigated whether pairing GLP-1 agonism (metabolic correction) with cyclophilin inhibition (fibrosis and inflammation remodeling) would yield additive or emergent benefits. Thus, we evaluated Semaglutide, Rencofilstat (CRV431), and their co-administration in a C57BL/6J model of diet- and toxin-induced MASLD via a Western diet, sucrose supplementation, and chronic carbon tetrachloride exposure. Semaglutide monotherapy significantly reduced body weight and decreased HCC burden (Kruskal-Wallis Analysis, p < 0.0001) whereas fibrosis quantified by picrosirius red staining did not differ significantly across the treatment groups (Welch's Analysis of Variance, p = 0.1725). Co-therapy did not improve collagen deposition compared with monotherapy. These findings indicate that the combination of GLP-1 receptor agonism with cyclophilin inhibition does not confer additive antifibrotic benefits in this advanced MASLD model, underscoring stage-dependent constraints on therapeutic synergy.